FDA releases the form FDA-483 with three observations from an inspection at India’s Eugia Pharma Specialties Limited.
FDA proposes not to include semaglutide, tirzepatide, and liraglutide on the 503 Bulks List of drugs that can be legally compounded from bulk substances.
FDA releases the form FDA-483 with three observations from an inspection at India’s Eugia Pharma Specialties Limited.
FDA proposes not to include semaglutide, tirzepatide, and liraglutide on the 503 Bulks List of drugs that can be legally compounded from bulk substances.
The CDER Office of Prescription Drug Promotion cautions Bayer that a video and TV ad for its Nubeqa omit important risk information and contain elements that make it difficult to comprehend the major statements.
A Clinical Trial Vanguard online post makes the case for further FDA guidance so drug trial sponsors can successfully incorporate artificial intelligence into their work.
